The Journal of clinical endocrinology and metabolism · 2026
Metastatic Disease in Phaeochromocytomas and Paragangliomas in Various Genotypes-A Systematic Review and Meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Svendsen Louise Kirkegaard, Rasmussen Åse Krogh, Klose Marianne Christina, Krogh Jesper, Feldt-Rasmussen Ulla
Аннотация
BACKGROUND: Paragangliomas and phaeochromocytomas (PPGLs) are rare neuroendocrine tumours with 10% to 20% of patients developing metastatic disease. The tumors exhibit a high degree of heritability, and pathogenic genetic variants have been associated with metastases.
OBJECTIVE: We aimed to investigate the association between the genotype of PPGL patients and their risk of metastatic disease, adjusting for time.
METHODS: A systematic search was conducted in PubMed and Embase. The primary outcome was the rate of metastatic disease per 100 followed patient-years analyzed through meta-analyses.
RESULTS: A significantly increased rate of metastatic disease per 100 followed patient-years was observed in all pathogenic germline variants included in the analyses, compared to the group with no identified variant. The group with no variant had a rate of 1.55 per 100 patient-years. SDHA, SDHC, SDHD, VHL, RET, NF1, and MAX had rates of 13.73, 6.27, 2.03, 2.34, 1.91, 4.11, and 9.66, respectively. The rate of SDHB is not presented as statistical heterogeneity exceeded 75%. The pathogenic somatic variant EPAS1 showed a rate of 3.82. Cluster-divided meta-analyses resulted in rates of 4.41 and 3.0 for cluster 1 and cluster 2, respectively. Meta-regression analysis revealed a 2.3-fold higher rate for the SDHB variant compared to the other cluster 1 variants.
CONCLUSION: We present associations between genotype and metastatic disease in PPGL patients. Our results indicate that patients harboring a pathogenic genetic variant have a higher rate of metastases compared to patients with no identified variant. High heterogeneity in several analyses suggests that further large cohort studies are needed.
OBJECTIVE: We aimed to investigate the association between the genotype of PPGL patients and their risk of metastatic disease, adjusting for time.
METHODS: A systematic search was conducted in PubMed and Embase. The primary outcome was the rate of metastatic disease per 100 followed patient-years analyzed through meta-analyses.
RESULTS: A significantly increased rate of metastatic disease per 100 followed patient-years was observed in all pathogenic germline variants included in the analyses, compared to the group with no identified variant. The group with no variant had a rate of 1.55 per 100 patient-years. SDHA, SDHC, SDHD, VHL, RET, NF1, and MAX had rates of 13.73, 6.27, 2.03, 2.34, 1.91, 4.11, and 9.66, respectively. The rate of SDHB is not presented as statistical heterogeneity exceeded 75%. The pathogenic somatic variant EPAS1 showed a rate of 3.82. Cluster-divided meta-analyses resulted in rates of 4.41 and 3.0 for cluster 1 and cluster 2, respectively. Meta-regression analysis revealed a 2.3-fold higher rate for the SDHB variant compared to the other cluster 1 variants.
CONCLUSION: We present associations between genotype and metastatic disease in PPGL patients. Our results indicate that patients harboring a pathogenic genetic variant have a higher rate of metastases compared to patients with no identified variant. High heterogeneity in several analyses suggests that further large cohort studies are needed.